echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Express more than 2 billion U.S. dollars to help develop anti-TIGIT antibodies, GSK adds a new generation of cancer immunotherapy

    Express more than 2 billion U.S. dollars to help develop anti-TIGIT antibodies, GSK adds a new generation of cancer immunotherapy

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎The content team editor of WuXi AppTec today, GlaxoSmithKline (GSK) and iTeos Therapeutics jointly announced that they will jointly develop and promote the anti-TIGIT antibody EOS-448, which is in phase 1 clinical development
    .

    The press release issued by GSK pointed out that this collaboration allows GSK to have three different targets (TIGIT, CD96 and PVRIG) related to the CD226 immune checkpoint pathway in research antibody therapies
    .

    They may have a synergistic effect and enhance the effectiveness of cancer immunotherapy
    .

    CD226 is a costimulatory receptor expressed on the surface of T lymphocytes and natural killer (NK) cells
    .

    It can activate T/NK lymphocytes in combination with CD155 and CD112 expressed on the surface of tumor cells
    .

    However, other immune checkpoint proteins are also expressed on the surface of T/NK cells, including CD96, TIGIT, and PVRIG in addition to the well-known PD-1
    .

    These immune checkpoint proteins bind to CD155 and CD112, preventing them from binding to CD226, thereby inhibiting the activation of T/NK cells
    .

    Preliminary studies of GSK have verified the important role of CD226 signaling pathway in oncology
    .

    Therefore, the company has developed an antibody therapy targeting CD96 GSK'608 and an antibody therapy targeting PVRIG GSK'562
    .

    These next-generation immune checkpoint inhibitors, combined with the company's recently approved PD-1 inhibitor Jemperli (dostarlimab), may have the potential to transform the treatment of multiple cancer types
    .

    ▲ GSK's R&D layout for the CD226 signaling pathway (picture source: reference [2]) EOS-448 developed by iTeos is an anti-TIGIT monoclonal antibody with multiple mechanisms of action
    .

    Through cooperation with iTeos, GSK’s R&D pipeline will have in-development antibody therapies targeting CD96, TIGIT, and PVRIG, providing more diversified tools for the further construction of cancer immune combination therapies
    .

    ▲EOS-448 has multiple mechanisms of action (picture source: reference [3]) According to the agreement, iTeos will receive an upfront payment of US$625 million and an additional US$1.
    45 billion in potential milestone payments
    .

    GSK and iTeos will share the development costs and responsibilities of EOS-448
    .

    Dr.
    Hal Barron, Chief Scientific Officer and President of R&D of GSK, said: “Immuno-oncology has brought about a major change in cancer treatment, but less than 30% of patients respond to the current commonly used immune checkpoint inhibitors
    .

    Based on scientific research, We believe that the combination of PD-1, TIGIT, CD96 and PVRIG inhibitors may revolutionize the treatment of multiple cancer types
    .

    We are very happy to work with the iTeos team to jointly develop the next generation of cancer immunotherapies
    .

    "Related reading: Favored by Roche, Gilead Sciences, etc.
    , why TIGIT has become an emerging target for cancer immunity Reference materials: [1] GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next -generation immuno-oncology combinations.
    Retrieved June 14, 2021, from https:// JP Morgan Healthcare Conference.
    Retrieved June 14, 2021, from https:// Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti- TIGIT antibody, monotherapy shows favorable tolerability profile and early signs of clinical activity in immune-resistant advanced cancers.
    Retrieved June 14, 2021, from https:// 20poster%20AACR%202021_final%20210325.
    pdf Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
    .

    If you need guidance on the treatment plan, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.